Entering text into the input field will update the search result below

ImmunoGen's Data For Ovarian Cancer Primes It Up For Several Catalysts Near-Term And In 2022

Dec. 04, 2021 3:39 AM ETImmunoGen, Inc. (IMGN)RHHBF, RHHBY12 Comments


  • ImmunoGen announced positive results from the phase 3 SORAYA trial using mirvetuximab for ovarian cancer patients, meeting both the primary and secondary endpoints.
  • A pivotal confirmatory study using mirvetuximab, known as MIRASOL, is expected to have results out by Q3 of 2022. This confirmatory study is a crucial turning point for the company.
  • BLA filing of mirvetuximab for patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer expected Q1 of 2022.
  • Initial data using IMGN632 with VIDAZA or VENCLEXTA to treat patients with acute myeloid leukemia (AML) to be shown at the 2021 American Society of Hematology (ASH) Annual Meeting in December of 2021.
  • This idea was discussed in more depth with members of my private investing community, Biotech Analysis Central. Learn More »

Doctor working in lab during COVID-19 outbreak

Morsa Images/DigitalVision via Getty Images

ImmunoGen (NASDAQ:IMGN) is a good biotech to watch. That's because it had recently reported positive results from the pivotal Phase 3 SORAYA trial. It used its drug mirvetuximab alone to treat patients with folate

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis profile picture
Actionable ideas on small-large cap biotech stocks through deep analysis.

I am the Founder of Biotech Analysis Central, A subscription service on Seeking Alpha's Marketplace. If you want to learn more about biotech investing or you want to check out my biotech analysis you can do so with a free 2-week trial to my service. Just hit the "Learn More" button on the bottom of the Marketplace Research Tab. I have a Bachelors of Applied Science Degree In Technology Management, Industrial and Business Services Management from St. Petersburg College Florida. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks. I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha.

You can follow me on stocktwits.com under the name BiopharmaPro where I currently have (62.5K) followers. Join me in my quest to find the best biotechnology stocks that deliver results to help patients with new treatment options.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.